Neuronetics Inc. announces efficacy of treatment for neurohealth disorders
pharmafile | January 18, 2023 | News story | Research and Development |
US-based commercial-stage medical technology company Neuronetics Inc., which focuses on designing, developing and marketing products that improve the quality of life for patients suffering from neurohealth disorders, has announced the efficacy of its NeuroStar Advanced Therapy for adult patients who suffer from both anxiety symptoms and major depressive disorder (MDD), known as anxious depression.
NeuroStar Advanced Therapy is a non-drug, noninvasive treatment. It is a transcranial magnetic stimulation (TMS) treatment, which is FDA-approved for adults with MDD, as part of treatment for adults with OCD, and to decrease anxiety symptoms in adult patients with MDD.
Researchers published a peer-reviewed publication in the Journal of Clinical Psychiatry, presenting real-world data proving the efficacy of NeuroStar Advanced Therapy. Researchers used data from the world’s largest depression outcomes registry of more than 15,000 patients to analyse a sample of over 1,800 patients. These patients, with MDD and moderate-to-severe anxiety symptoms, were treated with NeuroStar.
Patients with anxious depression exhibited clinically meaningful anxiety symptom improvement and antidepressant effects. The findings also showed that improvement in depressive symptoms was not related to the patient’s baseline anxiety severity, with all groups experiencing strong and nearly-equivalent antidepressant effects.
Dr Todd Hutton, M.D., Chief Medical Director at Southern California TMS Center, stated: “In my years of psychiatric practice, I have seen many depressed patients experiencing significant anxiety symptoms that can be debilitating. These results are impressive because they further illustrate the mental health benefits that NeuroStar TMS can provide for many patients with psychiatric disorders like anxious depression. Having access to this large registry allows us to further the research and establish best practices for treating physicians.”